Exagen Correlations
XGN Stock | USD 3.75 0.13 3.59% |
The current 90-days correlation between Exagen Inc and Fonar is 0.15 (i.e., Average diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Exagen Correlation With Market
Significant diversification
The correlation between Exagen Inc and DJI is 0.07 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Exagen Inc and DJI in the same portfolio, assuming nothing else is changed.
Exagen |
Moving against Exagen Stock
0.35 | DRMA | Dermata Therapeutics | PairCorr |
0.35 | DVAX | Dynavax Technologies | PairCorr |
0.33 | DTIL | Precision BioSciences Earnings Call This Week | PairCorr |
0.32 | VALN | Valneva SE ADR | PairCorr |
0.61 | VSTM | Verastem | PairCorr |
0.47 | VRNA | Verona Pharma PLC | PairCorr |
0.46 | VTGN | VistaGen Therapeutics | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Exagen Stock performing well and Exagen Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Exagen's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
FONR | 1.35 | (0.07) | 0.00 | (0.22) | 0.00 | 2.50 | 10.83 | |||
BNR | 3.85 | (0.13) | 0.00 | (0.34) | 0.00 | 8.52 | 26.46 | |||
SERA | 3.43 | (0.83) | 0.00 | (0.79) | 0.00 | 6.45 | 26.54 | |||
OLK | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
LMDX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
GTH | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
CSTL | 2.46 | (0.47) | 0.00 | (2.19) | 0.00 | 4.51 | 23.81 | |||
SHC | 1.40 | (0.04) | 0.00 | (0.14) | 0.00 | 2.40 | 12.51 | |||
PMD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
DRIO | 6.32 | 0.56 | 0.07 | (1.44) | 8.91 | 11.29 | 121.18 |
Exagen Corporate Management
Jeffrey Black | Chief Officer | Profile | |
Debra Zack | Chief Officer | Profile | |
John Wegener | Senior Marketing | Profile | |
Ryan Douglas | Investors Officer | Profile | |
Mark Hazeltine | Chief Officer | Profile | |
MingChou Lee | Chief Officer | Profile |